Outcome and prognostic factors in bronchial carcinoids: A single-center experience

Journal of Thoracic Oncology

Volumn 8, Issue 10, 2013, Pages 1282-1288

  Filosso, Pier Luigi ^a   Oliaro, Alberto ^a   Ruffini, Enrico ^a   Bora, Giulia ^a   Lyberis, Paraskevas ^a   Asioli, Sofia ^a   Delsedime, Luisa ^a   Sandri, Alberto ^a   Guerrera, Francesco ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Atypical carcinoid; Distant metastases; Lymph nodal metastases; Neuroendocrine tumors; Prognostic factors; Typical carcinoid

Indexed keywords

CISPLATIN; ETOPOSIDE; KI 67 ANTIGEN; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADOLESCENT; ADULT; AGED; ARTICLE; ATYPICAL CARCINOID; BRONCHOSCOPY; BRONCHUS; BRONCHUS CARCINOID; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; COUGHING; CUSHING SYNDROME; DISEASE FREE INTERVAL; DISTANT METASTASIS; DYSPNEA; ENCEPHALITIS; FEMALE; FEVER; FLUSHING; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEMOPTYSIS; HISTOLOGY; HUMAN; HUMAN TISSUE; LOBECTOMY; LUNG; LUNG RESECTION; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLEURA EFFUSION; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RADICAL RESECTION; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; SURVIVAL RATE; SYSTEMATIC LYMPHADENECTOMY; THORAX PAIN; TRANSTHORACIC ASPIRATION; TYPICAL CARCINOID; VERY ELDERLY; WEDGE RESECTION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRONCHIAL NEOPLASMS; CARCINOID TUMOR; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84892384319     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31829f097a     Document Type: Article

References (36)

1. Travis WD. Lung tumours with neuroendocrine differentiation. Eur J Cancer 2009;45 Suppl 1:251-266.
2. Travis WD, World Health Organization., International Agency for Research on Cancer., International Association for the Study of Lung Cancer., International Academy of Pathology. Pathology And Genetics of Tumours Of The Lung, Pleura, Thymus And Heart. LyonOxford: IARC Press Oxford University Press; 2004, 344 P.
3. Churg A, Warnock ML. Pulmonary tumorlet. A form of peripheral carcinoid. Cancer 1976;37:1469-1477.
4. Ferolla P, Daddi N, Urbani M, et al.; Regional Multidisciplinary Group for the Diagnosis and Treatment of Neuroendocrine Tumors, CRO, Umbria Region Cancer Network, Italy. Tumorlets, multicentric carcinoids, lymph-nodal metastases, and long-term behavior in bronchial carcinoids. J Thorac Oncol 2009;4:383-387.
5. Fink G, Krelbaum T, Yellin A, et al. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest 2001;119:1647-1651.
6. Travis WD. Advances in neuroendocrine lung tumors. Ann Oncol: Official J Eur Soc Med Oncol/ESMO. 2010;21 Suppl 7:65-71, vii.
7. Wurtz A, Benhamed L, Conti M, Bouchindhomme B, Porte H. Results of systematic nodal dissection in typical and atypical carcinoid tumors of the lung. J Thorac Oncol 2009;4:388-394.
8. Detterbeck FC. Management of carcinoid tumors. Ann Thorac Surg 2010;89:998-1005.
9. Ferguson MK, Landreneau RJ, Hazelrigg SR, et al. Long-term outcome after resection for bronchial carcinoid tumors. Eur J Cardiothorac Surg 2000;18:156-161.
10. Naalsund A, Rostad H, Strøm EH, Lund MB, Strand TE. Carcinoid lung tumors-incidence, treatment and outcomes: a population-based study. Eur J Cardiothorac Surg 2011;39:565-569.
11. Beasley MB, Thunnissen FB, Brambilla E, et al. Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol 2000;31:1255-1265.
12. Cardillo G, Sera F, Di Martino M, et al. Bronchial carcinoid tumors: nodal status and long-term survival after resection. Ann Thorac Surg 2004;77:1781-1785.
13. Filosso PL, Rena O, Donati G, et al. Bronchial carcinoid tumors: surgical management and long-term outcome. J Thorac Cardiovasc Surg 2002;123:303-309.
14. Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998;22:934-944.
15. R usch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P; Members of IASLC Staging Committee. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2009;4:568-577.
16. Travis WD, Giroux DJ, Chansky K, et al.; International Staging Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM classification for Lung Cancer. J Thorac Oncol 2008;3:1213-1223.
17. Lardinois D, De Leyn P, Van Schil P, et al. ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. Eur J Cardiothorac Surg 2006;30:787-792.
18. Granberg D, Wilander E, Oberg K, Skogseid B. Prognostic markers in patients with typical bronchial carcinoid tumors. J Clin Endocrinol Metab 2000;85:3425-3430.
19. Das-Neves-Pereira JC, Bagan P, Milanez-de-Campos JR, et al. Individual risk prediction of nodal and distant metastasis for patients with typical bronchial carcinoid tumors. Eur J Cardiothorac Surg 2008;34:473-7; discussion 477.
20. R ugge M, Fassan M, Clemente R, et al. Bronchopulmonary carcinoid: phenotype and long-term outcome in a single-institution series of Italian patients. Clin Cancer Res 2008;14:149-154.
21. El Jamal M, Nicholson AG, Goldstraw P. The feasibility of conservative resection for carcinoid tumours: is pneumonectomy ever necessary for uncomplicated cases? Eur J Cardiothorac Surg 2000;18:301-306.
22. Thomas CF Jr, Tazelaar HD, Jett JR. Typical and atypical pulmonary carcinoids: outcome in patients presenting with regional lymph node involvement. Chest 2001;119:1143-1150.
23. García-Yuste M, Matilla JM, Alvarez-Gago T, et al. Prognostic factors in neuroendocrine lung tumors: a Spanish Multicenter Study. Spanish Multicenter Study of Neuroendocrine Tumors of the Lung of the Spanish Society of pneumonology and thoracic surgery (EMETNE-SEPAR). Ann Thorac Surg 2000;70:258-263.
24. R usch VW, Klimstra DS, Venkatraman ES. Molecular markers help characterize neuroendocrine lung tumors. Ann Thorac Surg 1996;62:798-809; discussion 809.
25. Lin O, Olgac S, Green I, Zakowski MF, Klimstra DS. Immunohistochemical staining of cytologic smears with MIB-1 helps distinguish lowgrade from high-grade neuroendocrine neoplasms. Am J Clin Pathol 2003;120:209-216.
26. Costes V, Marty-Ané C, Picot MC, et al. Typical and atypical bronchopulmonary carcinoid tumors: a clinicopathologic and KI-67-labeling study. Hum Pathol 1995;26:740-745.
27. Pelosi G, Bresaola E, Bogina G, et al. Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol 1996;27:1124-1134.
28. R indi G, Klöppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007;451:757-762.
29. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010;39:707-712.
30. Yendamuri S, Gold D, Jayaprakash V, Dexter E, Nwogu C, Demmy T. Is sublobar resection sufficient for carcinoid tumors? Ann Thorac Surg 2011;92:1774-8; discussion 1778.
31. Granberg D, Eriksson B, Wilander E, et al. Experience in treatment of metastatic pulmonary carcinoid tumors. Ann Oncol 2001;12:1383-1391.
32. Wirth LJ, Carter MR, Jänne PA, Johnson BE. Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer 2004;44:213-220.
33. Filosso PL, Ruffini E, Oliaro A, Papalia E, Donati G, Rena O. Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide. Eur J Cardiothorac Surg 2002;21:913-917.
34. Bondanelli M, Ambrosio MR, Zatelli MC, Cavazzini L, Al Jandali Rifa'y L, degli Uberti EC. Regression of liver metastases of occult carcinoid tumor with slow release lanreotide therapy. World J Gastroenterol 2005;11:2041-2044.
35. R aut CP, Kulke MH. Targeted therapy in advanced well-differentiated neuroendocrine tumors. Oncol 2011;16:286-295.
36. Zatelli MC, Minoia M, Martini C, et al. Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids. Endocr Relat Cancer 2010;17:719-729.